Article
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.
Clinical genitourinary cancer - 1 Oct 2024
Souza Vinicius Carrera, Monteiro Fernando Sabino Marques, Maluf Fernando Cotait, Werutsky Gustavo, Fabrício Vanessa de Carvalho, Gidekel Rosemarie, Gandur-Quiroga Maria Natalia, Freitas Marcelo Roberto Pereira, Luz Murilo, Campos-Gomez Saul, Junior Jose Augusto Rinck, Bastos Diogo Assed, Sade Juan Pablo, da Trindade Karine Martins, Mota Augusto Cesar de Andrade, Fernandes Roni de Carvalho, Ruíz Allan Omar Barillas, Pereira E Silva Breno Dauster, de Oliveira Fernando Nunes Galvão, Cutuli Hernan Javier, Nogueira Lucas, Aceituno Luis Fernando García, Fernandez Mauricio, Inman Eva, Caitano Manuel, Herchenhorn Daniel, Ardila-Salcedo Jaime, Pacheco Patrícia, de Jesus Rafaela Gomes, Gössling Gustavo, Soares Andrey, Fay André Poisl
Abstract excerpt
INTRODUCTION: Fibroblast growth factor receptor (FGFR) mutations and fusions are relevant biomarkers in metastatic urothelial carcinoma (mUC). However, the prevalence of genomic alterations and their impact on clinical outcomes in a Latin American population remains unknown. This study aimed to explore the prevalence of FGFR mutations and/or fusions in patients with mUC in Latin America (LATAM) and its...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.